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Abstract
Background: Calcium (Ca2+) has recently been shown to selectively increase the activity of
monoamine oxidase-A (MAO-A), a mitochondria-bound enzyme that generates peroxyradicals as
a natural by-product of the deamination of neurotransmitters such as serotonin. It has also been
suggested that increased intracellular free Ca2+ levels as well as MAO-A may be contributing to the
oxidative stress associated with Alzheimer disease (AD).
Results: Incubation with Ca2+ selectively increases MAO-A enzymatic activity in protein extracts
from mouse hippocampal HT-22 cell cultures. Treatment of HT-22 cultures with the Ca2+
ionophore A23187 also increases MAO-A activity, whereas overexpression of calbindin-D28K
(CB-28K), a Ca2+-binding protein in brain that is greatly reduced in AD, decreases MAO-A activity.
The effects of A23187 and CB-28K are both independent of any change in MAO-A protein or gene
expression. The toxicity (via  production of peroxyradicals and/or chromatin condensation)
associated with either A23187 or the AD-related β-amyloid peptide, which also increases free
intracellular Ca2+, is attenuated by MAO-A inhibition in HT-22 cells as well as in primary
hippocampal cultures.
Conclusion: These data suggest that increases in intracellular Ca2+ availability could contribute to
a MAO-A-mediated mechanism with a role in AD-related oxidative stress.
Background
MAO-A and MAO-B, two isoforms of monoamine oxidase
(MAO), are expressed on the mitochondrial outer mem-
brane. MAO-mediated neurodegeneration can result from
the formation of hydrogen peroxide (H2O2) as a by-prod-
uct of metabolism of aminergic neurotransmitters includ-
ing serotonin and dopamine. If it is not detoxified by
antioxidant systems such as glutathione peroxidase – one
of the most abundant such systems in brain [1] – then
H2O2 can be converted by iron-mediated Fenton reactions
to hydroxyl radicals that can initiate lipid peroxidation
and cell death. This is exacerbated when antioxidant sys-
tems are compromised, such as during aging [2]. The
reduction in the efficacy of these systems may simply be
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aggravated in chronic disease states such as Alzheimer dis-
ease (AD)[3].
It has been demonstrated that inhibitors of MAO-B, such
as l-deprenyl and, more recently, rasagiline, are effective
in the management of early symptoms of Parkinson's dis-
ease in the clinic and in animal models [4-6] as well as in
patients with mild AD-type dementia [4,7]. Both MAO-B-
positive astrocytes [8] and reactive oxygen species (ROS)
[9] have been found in the vicinity of β-amyloid (Aβ)
plaques. L-Deprenyl and rasagiline, however, may exert
some of their effects independently of MAO-B as the neu-
roprotection mediated by these drugs is often associated
with concentrations of the drug that are well below those
required for inhibition of the enzyme [6], and has been
associated with activation of Bcl-2 family members, inter-
actions with the mitochondrial pore complex, and modu-
lation of amyloid precursor protein cleavage [4].
MAO-A also plays a role in neuropsychiatric and behavio-
ral disorders. The importance of this isoform is suggested
by the aggressive phenotype seen in male mice deficient in
MAO-A [10] and in males in a Dutch kindred bearing a
spontaneous mutation (resulting in a premature stop) in
the  mao-A  gene [11]. Similarly, maltreated children,
whose genotype confers low levels of MAO-A expression,
more often develop conduct disorder, antisocial personal-
ity and adult violent crime than do children with a high-
activity MAO-A genotype [12]. Relatively modest changes
in MAO-A activity/function can have important neuropsy-
chiatric consequences as demonstrated by the fact that
[11C]-harmine-labeled MAO-A is elevated by only 34%
throughout the brain of untreated depressed patients
compared to controls, yet it appears to be the major con-
tributor to monoamine metabolism in these same
patients [13]. Depression not only may promote cognitive
impairment, but also may be a risk factor for AD [14]. Not
surprisingly, MAO-A, which is often targeted for the treat-
ment of depression, is also a potential risk factor for late-
onset AD [15-18]. In contrast to irreversible inhibitors of
MAO-A such as clorgyline, reversible inhibitors such as
moclobemide are better tolerated and have been particu-
larly efficacious in treating depression [19,20] and cogni-
tive disorders [21] in the elderly. In addition, they protect
against apoptosis [22] and glutamate-induced excitotoxic-
ity [23]in vitro. Inhibition of MAO-A activity protects
against striatal damage produced by the mitochondrial
poison malonate and appears to rely on attenuation of
dopamine-derived ROS [24], while apoptosis following
serum starvation is reduced in MAO-A deficient cortical
brain cells [25].
The NMDA-subtype of glutamate receptor has been linked
to massive increases in mitochondrial Ca2+ accumulation
[26]. It is interesting that activation of this same receptor
has been linked to Ca2+-dependent processes and pathol-
ogy in [hepatic] encephalopathic brains [27] that corre-
lates with a selective increase in MAO-A activity [28]. The
selectivity of Ca2+ for MAO-A is demonstrated ex vivo using
brains from monkey [29], mouse [30] and rat [31], and is
supported by the ability of the Ca2+-channel antagonist
nimodipine to block the selective increase in MAO-A
activity observed in senescence-accelerated mouse brain
[32]. Additional cations able to influence MAO-A func-
tion include Zn2+, which inhibits MAO-A activity [29],
and Al3+ (another ion often linked to AD-like pathology),
which activates it [33].
These combined observations, in addition to the fact that
cytoplasmic free Ca2+ is elevated in aged neurons and even
more so during neurodegeneration, such as that encoun-
tered during in AD [15,34-36], certainly argue for exami-
nation of the relation between Ca2+ and MAO.
Methods
Antibodies and reagents
5-Hydroxytryptamine (5-HT), β-phenylethylamine
(PEA), the β-actin antibody and protease inhibitor cock-
tail were bought from Sigma-Aldrich Co. [14C]-5-HT
(NEC-225) and [14C]-PEA (NEC-502) were purchased
from PerkinElmer Life Sciences. The MAO-A and CB-28K
antibodies were purchased from Santa Cruz Biotechnol-
ogy. IgG-HRP conjugates were obtained from Cedarlane
Laboratories. All other reagents were purchased commer-
cially.
Immortalized hippocampal cell cultures
The immortalized mouse hippocampal HT-22 cell line
[20] was kindly provided by Dr. P. Maher (The Scripps
Research Institute, La Jolla, CA, USA). Cells were cultured
(5% CO2 at 37°C) in DMEM/low glucose medium con-
taining 10% fetal bovine serum, 100 IU/mL penicillin G
sodium salt and 0.03% glutamine.
Monoamine oxidase (MAO) activity
MAOA and -B activities (nmol/hr/mg protein) in HT-22
cell cultures were estimated radiochemically [37]. Briefly,
samples were homogenized in 80 volumes of oxygenated
potassium phosphate buffer (0.2 M, pH 7.8) and incu-
bated (100 µg/100 µl) for 10 min at 37°C with either 250
µM [14C]-5-HT (for MAO-A activity) or 50 µM [14C]-β-PEA
(for MAO-B activity). The incubation was terminated by
acidification and the labeled metabolites were extracted
into ethyl acetate/toluene (1:1 vol/vol, water-saturated),
an aliquot of which was subjected to scintillation spec-
trometry to determine radioactive content. MAO-A sub-
strate kinetics was determined using protein (100 µg per
reaction) from HT-22 cells pre-incubated in the absence
or presence of Ca2+ (1 mM; 20 min, room temperature)
and subsequently incubated with increasing concentra-BMC Neuroscience 2007, 8:73 http://www.biomedcentral.com/1471-2202/8/73
Page 3 of 10
(page number not for citation purposes)
tions of [14C]-5-HT [15 µM-4 mM]. Incubation in oxygen-
ated potassium phosphate buffer (0.2 M, pH 7.8) and
extraction of labeled metabolites proceeded as described
above. Data were analyzed for estimates of Km and Vmax
using the Prism v3.01 software.
Transient overexpression of CB-28K
The pREP-CB-28K (calbindin-D28K) plasmid expression
vector was kindly  provided by Dr. A. Pollock (University
of California, San Francisco, CA). HT-22 cells were seeded
in log phase and transfected with plasmid DNA (1–2 µg/
well on a 24-well plate; seeded at 5 × 105 cells/well) using
ExGen™500 (Fermentas) according to the manufacturer's
directions. Expression of eGFP fluorescent protein
revealed a transfection efficiency of approximately 50%
using this technique. Cells were routinely harvested 24 h
post-transfection.
Immunodetection of target proteins
Treated HT-22 cells were washed twice with ice-cold PBS
and proteins were extracted in ice-cold lysis buffer (1%
Triton X-100, 10% glycerol, 1 mM EDTA, 20 mM Tris, pH
7.5), containing protease inhibitor cocktail and 1 mM
orthovanadate. Standard denaturing (SDS-PAGE) condi-
tions were used to resolve proteins, which were then trans-
ferred to nitrocellulose. Protein expression in total cell
lysates (20–30 µg/lane, precleared; 5000 × g, 10 min,
4°C) was visualized by enhanced chemiluminescence.
Depicted immunoblots are representative of two-three
independent experiments.
Determination of target mRNA by semi-quantitative 
reverse transcriptase-PCR (RT-PCR)
Total RNA from treated HT-22 cells was prepared with
TRIZOL reagent according to the manufacturer's protocol
and digested with RNase-free DNase to clear residual
genomic DNA. First strand cDNA was reverse-transcribed
from 2 µg of total RNA using oligo-(dT) (SuperScript™III
First-Strand Synthesis System, Invitrogen). The cDNA was
amplified using Taq polymerase and primer pairs (mao-A:
forward: 5'-GAA GCT GAG CTC TCC TGT TAC-3'; reverse:
5'-ACA AAG CAG AGA AGA GCC AC-3'; mao-B: forward:
5'-GCT GAA GAG TGG GAC TAC ATG AC-3'; reverse: 5'-
GGA ATG AAC CTT GGG AGG TG-3'; β-actin: forward: 5'-
TAG AAG CAT TTG CGG TGC ACG-3'; reverse: 5'-TGC
CCA TCT ATG AGG GTT ACG-3'). The resultant semi-
quantitative PCR products were electrophoresed on agar-
ose gel and visualized using ethidium bromide staining.
Fluorescence determination of free intracellular Ca2+
HT-22 cells were loaded with the fluorescent dye Fluo3-
acetoxymethyl ester (Fluo-3-AM; Molecular Probes) at 4
µM for 30 min at 37°C [36]. Fluorescence was visualized
at an excitation wavelength of 488 nm and an emission
wavelength of 550 nm on an Olympus FV300 Confocal
Laser Scanning Biological Microscope.
Visualization of cytoplasmic peroxide radicals
2',7'-Dihydrodichlorofluorescein diacetate (DCFH2-DA)
[37] permeates the cell membrane and is hydrolyzed to
DCFH2, a nonfluorescent compound that remains
trapped within the cell, but which yields a fluorescent
product upon oxidation by H2O2. The cells were seeded
on cover-slips. After treatment, the cells were rinsed twice
with PBS and incubated with DCFH2-DA (5 µM, 30 min
at 37°C) or DMSO, vehicle). The cells were washed in pre-
warmed HEPES-buffered (20 mM) HBSS (pH 7.0) con-
taining 5 mM glucose, and prepared for DCF fluorescence
(excitation: 488 nm; emission: 530 ± 15 nm).
Rat primary hippocampal culture
Animal care followed protocols and guidelines approved
by University of Saskatchewan Animal Care Committee
and the Canadian Council on Animal Care. Rat hippoc-
ampal cultures were prepared from E18 fetuses (time-
pregnant Sprague-Dawley rats; Charles River Canada,
Montreal, PQ, Canada) as described before with some
modifications [38]. In brief, the hippocampus was dis-
sected in Ca2+- and Mg2+-free Hank's balanced salt solu-
tion (HBSS) supplemented with 15 mM HEPES and
penicillin (100 U/ml)-streptomycin (100 µg/ml) (Gibco).
Collected tissues were digested at 37°C with 0.25%
trypsin-EDTA 15 min. The reaction was quenched with
fetal bovine serum (FBS, 10%) and tissues were rinsed 3–
4 times with HBSS to remove FBS. Following centrifuga-
tion at 800 × g for 10 min, the medium was removed and
cells were resuspended in a chemically defined serum-free
NeuroBasal medium supplemented with 1% N2, 2% B27,
50 µM L-glutamine, 15 mM HEPES, 10 U/ml penicillin
and 10 µg/ml streptomycin. Neurons were then plated on
coverslips (coated with 25 µg/ml poly-D-lysine), and
grown at 37°C with 5% CO2-humidified atmosphere. The
medium was replaced 24 h later with fresh NeuroBasal
medium lacking L-glutamine and antibiotics. Medium
was replaced after 4–5 days in vitro (DIV). Neurons were
treated on DIV 7, following which they were fixed with
4% paraformaldehyde in 0.01 M PBS for 20 min at room
temperature, washed several times with PBS, and stained
with Hoechst 33258 (500 ng/ml, 10 min) for microscopic
visualization of chromatin condensation (a characteristic
of apoptotic cell death).
Statistical analyses
Significance (set at P < 0.05) was assessed by unpaired t-
tests or by one-way ANOVA with post hoc analyses relying
on Bonferonni's Multiple Comparison Test (GraphPad
Prism v3.01). Data are represented as mean ± standard
deviation (SD).BMC Neuroscience 2007, 8:73 http://www.biomedcentral.com/1471-2202/8/73
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Results
Low millimolar concentrations of Ca2+ increase MAOA 
activity in HT-22 cells
MAO-A activity in HT-22 cell extracts incubated with Ca2+
(range: 0.1–10 mM) was increased, with a peak (~20%
above baseline) around 0.5–1 mM Ca2+ (Fig. 1A). Ca2+ did
not exert any effect on MAO-B activity (Fig. 1B). Mg2+ on
its own did not exert any effect on MAO-A activity, but it
did inhibit the effect of Ca2+ (Fig. 1C).
Examination of the kinetics of MAO-A activity in the pres-
ence of Ca2+ revealed a decrease in Km (µM) [97.6 ± 6.99
with Ca2+ vs. 125.8 ± 21.02 without Ca2+; n = 3, P  =
0.0462, t = 2.203, df = 4], indicating that Ca2+ facilitates
the enzymatic reaction. Vmax  (nmol/h/mg protein)
remained unchanged [74.4 ± 2.9 with Ca2+, vs. 72.4 ± 1.2
without Ca2+; n = 3, P = 0.1672, t = 1.051, df = 4], suggest-
ing that Ca2+ was acting via an allosteric mechanism (Fig.
2A,B). This was more evident on a double-reciprocal plot
of the data: the slope (e.g. Km/Vmax) was changed [0.0441
± 0.0009 (without Ca2+: r2 = 0.9973) vs. 0.0328 ± 0.0007
(with Ca2+: r2 = 0.9967)], whereas the y-intercept (e.g. 1/
Vmax) was not [3.13 ± 0.21e-4 (without Ca2+) vs. 3.20 ±
0.18e-4 (with Ca2+)] (Fig. 2C).
The Ca2+ ionophore A23187 increases MAO-A activity
HT-22 cells were treated with the Ca2+ ionophore A23187
(5 µM; 30 min) so as to examine the effect of increasing
Ca2+ availability on MAO-A activity in living cells. Fluores-
cence microscopy (Fig. 3A) confirmed a significant
increase in free Ca2+ as well as a selective 43% increase in
MAO-A activity (control: 55.3 ± 9.4 nmol/h/mg protein
versus A23187: 79.1 ± 15.5 nmol/h/mg protein; n = 3, P =
0.0424, t = 2.270, df = 4) (Fig. 3B). MAO-A protein expres-
sion was unchanged compared to control levels (Fig. 3C).
The expression of mao-A  gene (expressed as a ratio to
GAPDH) was also not affected by A23187 treatment [con-
trol: 100.0% ± 11.2; A23187: 102.0% ± 2.1; n = 3, P =
0.7760, t = 0.3044, df = 4] (Fig. 3D, E). Neither MAO-B
activity [control: 18.92 ± 2.11 nmol/h/mg protein versus
A23187: 18.33 ± 1.74 nmol/h/mg protein; n = 3, P =
0.5914, t = 0.5826, df = 4] nor gene expression [control:
100.0% ± 4.5; with A23187: 92.0% ± 8.2; n = 3, P  =
0.2127, t = 1.481, df = 4] was affected by A23187. An
increase in cytoplasmic reactive oxygen species (ROS) was
observed, which was partly blocked by pretreatment with
the MAO-A inhibitor clorgyline (100 µM; 1 hour) (Fig.
3F).
Reduction of free intracellular Ca2+ by overexpression of 
CB-28K reduces MAO-A activity
HT-22 cells were transfected with either the vector control
(pREP) or the pREP-CB-28K expression plasmid (Fig. 4).
Overexpression of CB-28K (24 h) reduced the level of
intracellular free Ca2+ and decreased constitutive ROS lev-
els (Fig. 4A). Overexpressed CB-28K induced a decrease
(36%) in basal MAO-A activity [pREP: 69.4 ± 16.4 nmol/
h/mg protein versus pREP-CB-28K: 44.4 ± 10.2 nmol/h/
mg protein; n = 4, P = 0.0440, t = 2.246, df = 6] (Fig. 4B).
CB-28K overexpression was confirmed by western blot
(Fig. 4C) and it did not affect the expression of either mao-
A  gene (expressed as a ratio to β-actin) [with pREP:
100.0% ± 9.8; with pREP-CB-28K: 113.0% ± 9.9; n = 3, P
= 0.1116, t = 1.864, df = 4] or protein (Fig. 4D, E). Neither
MAO-B activity [pREP: 8.4 ± 0.47 nmol/h/mg protein ver-
sus pREP-CB-28K: 7.0 ± 3.22 nmol/h/mg protein; n = 4, P
= 0.4226, t = 0.8604, df = 6] nor gene expression [with
pREP: 100.0% ± 16.1; with pREP-CB-28K: 104.0% ± 17.3;
n = 3, P = 0.7841, t = 0.2930, df = 4] was affected by CB-
28K overexpression.
Effect of Ca2+ on MAO activity in the mouse hippocampal HT-22 cell line Figure 1
Effect of Ca2+ on MAO activity in the mouse hippocampal HT-22 cell line. HT-22 cell lysates (100 µg/100 µL; n = 4) 
were incubated with increasing concentrations of Ca2+ and assayed radioenzymatically for (A) MAO-A and (B) MAO-B activi-
ties. (C) HT-22 lysates (n = 3) were incubated with either Ca2+ or the Ca2+ antagonist Mg2+ (1 mM) or co-incubated with Ca2+ 
(1 mM) and increasing concentrations of Mg2+ to test for the potential of Mg2+ to block Ca2+ (1 mM)-sensitive MAO-A activity. 
**: P < 0.01, ***: P < 0.001 vs. control. Data represent mean ± SD.BMC Neuroscience 2007, 8:73 http://www.biomedcentral.com/1471-2202/8/73
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Immortalized and primary hippocampal toxicity 
associated with the Alzheimer disease-related peptide, Aβ, 
relies partly on a MAO-A sensitive mechanism
HT-22 cells treated with the AD-related Aβ(1–40) peptide
(30 µM; 48 h) had significantly more free Ca2+ (Fig. 5A,
top panels) and a corresponding increase in ROS produc-
tion (Fig. 5A, middle panels) that was decreased by pre-
treatment with the MAO-A inhibitor clorgyline (100 µM,
1 h) (Fig. 5A, bottom panels). Hoechst staining, which
labels all cell nuclei including those that have chromatin
condensation (a sign of apoptotic processing), revealed a
significant increase in apoptotic primary hippocampal
neurons in cultures treated with Aβ(1–42) (10 µM, 24 h)
(Fig. 5B) [F(4,11) = 69.16, P < 0.0001]. Post-hoc analysis
revealed that the effect of Aβ(1–42) [P  < 0.001] was
greatly attenuated by pre-treatment with the MAO-A
inhibitor clorgyline (100 µM; 1 h) [P < 0.01] (Fig. 5C).
The Ca2+ ionophore A23187 increases MAO-A activity Figure 3
The Ca2+ ionophore A23187 increases MAO-A activity. (A) Levels of free intracellular Ca2+, [Ca2+]i, in HT-22 cells 
treated with A23187 (5 µM: 30 min) were determined using the Ca2+-binding Fluo-3 AM fluorescent dye. (B) MAO-A and 
MAO-B activities were assessed radioenzymatically in A23187-treated cell cultures (*P < 0.05 versus control levels). (C) MAO-
A protein expression was determined in SDS-PAGE resolved total cell lysates. Levels of β-actin demonstrate equal protein 
loading. (D) Densitometry graph representing mao-A gene expression (as a ratio to GAPDH expression) determined using semi-
quantitative RT-PCR amplification of mRNA extracted from A23187-treated cell cultures. (E) Representative RT-PCR amplifi-
cation fragments. (F) In similarly-treated cells, the production of ROS was assessed using the H2O2-binding DCF fluorogen. A 
parallel series of cell cultures were pre-treated with the specific MAO-A inhibitor, clorgyline (CLG; 100 µM, 1 h). Data repre-
sent mean ± SD.
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Effect of Ca2+ on MAO-A substrate kinetics in HT-22 hippocampal cell line Figure 2
Effect of Ca2+ on MAO-A substrate kinetics in HT-22 hippocampal cell line. (A) HT-22 cell lysates (100 µg/100 µL; n 
= 3) were incubated with increasing concentrations of substrate, e.g. [14C]-5-HT in the absence (❍ ) or presence (● ) of Ca2+ (1 
mM). The individual curves represent data pooled from three independent experiments. Data are presented as mean ± SD. (B) 
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Discussion
H2O2 is a natural by-product of MAO-A-mediated degra-
dation of amines [38]. The normal aging process and var-
ious neurodegenerative processes such as Parkinson's
disease [39] and Alzheimer's disease [40,41] could well be
affected by oxidative stress associated with enhanced
MAO-generated levels of H2O2.
We demonstrate that the selective response of MAO-A to
Ca2+ (and its sensitivity to Mg2+, a physiologic Ca2+ antag-
onist [42]) occurs in immortalized HT-22 hippocampal
cells and confirms observations using brain extracts from
monkey [29], mouse [30], rat [31] and human (DDM:
unpublished data). The effect of Ca2+ on MAO-A activity
in our cultures appears modest; however, Meyer et al [13]
have recently demonstrated that untreated depressed
patients have levels of MAO-A density that are only 34%
higher than that found in controls. Yet these same authors
propose that this modest change could account for most
of the change in biogenic amine levels observed in these
patients. Obviously, small changes in MAO-A can signifi-
cantly impact brain function.
While low millimolar levels of Ca2+ are necessary to reveal
this effect, the fact that MAO-B activity remains unaffected
clearly supports differences in MAO-A and MAO-B regula-
tion. The need for millimolar concentrations also suggests
pathological relevance. Interestingly, the mitochondria
can modulate cytoplasmic Ca2+ homeostasis by accumu-
lating Ca2+ into the very high micromolar range [43]. Fur-
thermore, elevated Ca2+  concentrations localized to
microdomains may also represent unique means of mod-
ulating localized mitochondrial membrane and/or matrix
function [44], including the activation of dehydrogenases
[45]. In neurons and chromaffin cells, mitochondria rap-
idly and reversibly buffer Ca2+ during cell stimulation to
help clear large Ca2+ loads [46-48]. The ensuing overload-
ing of mitochondria with Ca2+ may be involved in several
pathological conditions, including ischemia-reperfusion
lesions, neurotoxicity and neurodegenerative diseases,
where ATP depletion, overproduction of ROS and release
of apoptotic factors lead to cell damage [49].
Using the Ca2+ ionophore A23187, we now confirm that
increasing free intracellular Ca2+ well above normal levels
Overexpression of the Ca2+-binding protein CB-28K decreases MAO-A activity Figure 4
Overexpression of the Ca2+-binding protein CB-28K decreases MAO-A activity. HT-22 cells were transfected with 
the pREP plasmid (Vector) or the pREP-CB-28K expression vector (CB-28K). (A) The effect of CB-28K overexpression (24 h) 
on free intracellular Ca2+, [Ca2+]i, and on ROS production was examined. (note, the relative fluorescence intensity used for this 
set of ROS experiments was increased intentionally so as to avoid a "floor" effect, i.e. so that a decrease in ROS production 
could be demonstrated in CB-28K-overexpressing cells). (B) MAO-A and MAO-B activities were assessed radioenzymatically 
in corresponding cell lysates (*P < 0.05 versus control levels). (C) SDS-PAGE-resolved total cellular proteins were probed for 
CB-28K overexpression and for the expression of MAO-A and β-actin (used as a loading control). (D) Densitometry graph 
representing mao-A gene expression (relative to β-actin expression) determined by semi-quantitative RT-PCR, represented in 
(E). Data are presented as mean ± SD.
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selectively increases MAO-A activity in living hippocam-
pal HT-22 cells. The associated increase in peroxyradicals
is moderately decreased by MAO-A inhibition, supporting
a contribution by the enzyme to A23187-associated toxic-
ity. Intracellular Ca2+ levels can also be quenched by spe-
cific proteins including calbindin-28K (CB-28K), the
predominant Ca2+-binding protein in brain [50]. Overex-
pression of CB-28K in HT-22 cells significantly decreased
free Ca2+ levels and significantly decreased MAO-A activ-
ity. Again MAO-B activity was spared. The effects of both
A23187 and CB-28K occurred independent of any change
in the expression level of MAO-A protein (or mao-A gene),
which, in combination with our demonstration of affinity
changes of the MAO-A enzyme in the presence of Ca2+,
suggests a functional modification of the MAO-A protein
itself. These combined data implicate a CB-28K-depend-
ent, Ca2+-sensitive component to MAO-A function, which
could be exacerbated when CB-28K expression levels are
compromised, such as in normal aging or, more impor-
tantly, during neurodegenerative processes [16,34,51]. In
support of this, an age-related loss of CB-28K immunore-
active basal forebrain cholinergic neurons in cortical
regions and in the dentate gyrus (hippocampus) has been
shown in several species including dog, mouse and rat
[34] and references therein). Furthermore, in AD-related
pathology, a substantially greater loss of CB-28K immu-
noreactivity is observed, with the diminished capacity of
the cell to buffer intracellular Ca2+ being considered as a
core factor in the pathogenesis of AD [51-54]. This is cor-
roborated by the ability of ectopic CB-28K to protect cell
cultures against apoptosis, including that induced by the
AD-related peptide β-amyloid [55-58] and by the fact that
alterations in Ca2+ signalling can occur early in AD, well
before any obvious extracellular Aβ deposition [59]. Fur-
thermore, dihydropyridine Ca2+ channel blockers, which
are known to block the selective increase in MAO-A in the
senescence-accelerated mouse model [32], may improve
learning and performance in animals [60] and may
improve age-associated and AD-related memory impair-
ment in humans [61,62]. As CB-28K and MAO-A immu-
ROS production induced by the Alzheimer disease-related peptide, Aβ, is diminished by MAO-A inhibition Figure 5
ROS production induced by the Alzheimer disease-related peptide, Aβ, is diminished by MAO-A inhibition. 
HT-22 cells were treated with Aβ(1–40) (30 µM, 48 h). The effect of Aβ(1–40) on (A) free intracellular Ca2+, assessed using 
FLUO-3AM fluorescence, and on the production of ROS, assessed using the H2O2-binding DCF fluorogen. (B) Hoechst staining 
of primary hippocampal cell cultures was used to determine the proportion of cells exhibiting chromatin condensation (an indi-
cation of apoptotic cell death: arrows) in Aβ(1–42)-treated cultures. In both HT-22 cultures (A) and primary neuronal cultures 
(B), the effect of Aβ was reversed by pretreatment with the specific MAO-A inhibitor, clorgyline (CLG; 100 µM, 1 h). (C) 
Number of primary hippocampal cells (expressed as a percentage of control) that exhibit chromatin condensation following 
treatment with Aβ and/or CLG (groups shown in B). ***: P < 0.001 vs. control. ##: P < 0.01 between the indicated groups. 
Data are presented as mean ± SD.
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noreactivities are often co-localized and cells
immunoreactive for both proteins are reduced during AD
[54,63], it is not unreasonable to suppose that a loss of
CB-28K could facilitate MAO-A-mediated H2O2 produc-
tion in an increasingly toxic Aβ environment, leading to
localized cell death. Treatment with Aβ(1–40) increases
intracellular levels of Ca2+ [64] [present study], possibly
through its effect on the ryanodine receptor [65]. A path-
ological contribution by MAO-A in AD is further sug-
gested by the accumulation of toxic metabolites of MAO-
mediated deamination in AD patients [66] as well as by
the ability of MAO-A inhibition to reduce the ROS pro-
duction associated with treatment of HT-22 cells with the
AD-related Aβ(1–40) peptide (present study). Primary
hippocampal neuronal cultures are also particularly sensi-
tive to Aβ peptide [67] and Aβ-induced toxicity in these
cells is also sensitive to MAO-A inhibition (present study).
Experimentation based on in vivo assessment of the effect
of Ca2+ on MAO-A as well as a closer examination of the
relation between Ca2+/CB-28K and MAO-A in AD tissues
is warranted.
MAO-A is a risk factor in AD and changes in MAO-A activ-
ity parallel changes in the production of ROS, e.g. H2O2.
Given the neuroprotective role of CB-28K in human
pathologies such as AD (and in models of AD), in addi-
tion to our demonstration that the toxicity of the AD-
related peptide, Aβ, is sensitive to MAO-A inhibition, we
suggest that part of the oxidative stress associated with AD
may rely on a Ca2+/CB-28K-sensitive, MAO-A-mediated
mechanism.
Conclusion
The availability of free intracellular Ca2+ is positively cor-
related with the activity of MAO-A, a mitochondrial
H2O2-generating enzyme. The influence of Ca2+ on MAO-
A function could potentially impact AD-related pathol-
ogy, which is often associated with altered Ca2+ homeos-
tasis, mitochondrial dysfunction and oxidative stress.
Competing interests
The author(s) declares that there are no competing inter-
ests.
Authors' contributions
XC carried out the majority of the work. ZW purified and
cultured the primary hippocampal cells. GGG partici-
pated in the FLUO-3AM microscopy studies. XC, XL and
DDM drafted the manuscript. DDM conceived and
designed the study, and coordinated data collection and
analysis. All authors read, edited and approved the final
manuscript.
Acknowledgements
This work was funded, in part, by the Canadian Institutes of Health 
Research and by the Saskatchewan Health Research Foundation (DDM) 
and, in part, by the Aruna and Kripa Thakur award (XC), Department of 
Psychiatry, University of Saskatchewan. ZW is a recipient of a CIHR/Rx&D 
Research Program & AstraZeneca/Alzheimer Society of Canada Fellowship.
References
1. Sies H: Strategies of antioxidant defense.  European journal of bio-
chemistry / FEBS 1993, 215(2):213-219.
2. Zhu Y, Carvey PM, Ling Z: Age-related changes in glutathione
and glutathione-related enzymes in rat brain.  Brain research
2006, 1090(1):35-44.
3. Crack PJ, Cimdins K, Ali U, Hertzog PJ, Iannello RC: Lack of glu-
tathione peroxidase-1 exacerbates Abeta-mediated neuro-
toxicity in cortical neurons.  J Neural Transm 2006,
113(5):645-657.
4. Youdim MB, Edmondson D, Tipton KF: The therapeutic potential
of monoamine oxidase inhibitors.  Nature reviews 2006,
7(4):295-309.
5. Magyar K, Palfi M, Tabi T, Kalasz H, Szende B, Szoko E: Pharmaco-
logical aspects of (-)-deprenyl.  Current medicinal chemistry 2004,
11(15):2017-2031.
6. Magyar K, Szende B: (-)-Deprenyl, a selective MAO-B inhibitor,
with apoptotic and anti-apoptotic properties.  Neurotoxicology
2004, 25(1-2):233-242.
7. Riederer P, Lachenmayer L, Laux G: Clinical applications of
MAO-inhibitors.  Current medicinal chemistry 2004,
11(15):2033-2043.
8. Saura J, Luque JM, Cesura AM, Da Prada M, Chan-Palay V, Huber G,
Loffler J, Richards JG: Increased monoamine oxidase B activity
in plaque-associated astrocytes of Alzheimer brains revealed
by quantitative enzyme radioautography.  Neuroscience 1994,
62(1):15-30.
9. McLellan ME, Kajdasz ST, Hyman BT, Bacskai BJ: In vivo imaging of
reactive oxygen species specifically associated with thiofla-
vine S-positive amyloid plaques by multiphoton microscopy.
J Neurosci 2003, 23(6):2212-2217.
10. Shih JC, Chen K, Ridd MJ: Monoamine oxidase: from genes to
behavior.  Annual review of neuroscience 1999, 22:197-217.
11. Brunner HG, Nelen M, Breakefield XO, Ropers HH, van Oost BA:
Abnormal behavior associated with a point mutation in the
structural gene for monoamine oxidase A.  Science (New York,
NY 1993, 262(5133):578-580.
12. Caspi A, McClay J, Moffitt TE, Mill J, Martin J, Craig IW, Taylor A,
Poulton R: Role of genotype in the cycle of violence in mal-
treated children.  Science (New York, NY 2002, 297(5582):851-854.
13. Meyer JH, Ginovart N, Boovariwala A, Sagrati S, Hussey D, Garcia A,
Young T, Praschak-Rieder N, Wilson AA, Houle S: Elevated
monoamine oxidase a levels in the brain: an explanation for
the monoamine imbalance of major depression.  Archives of
general psychiatry 2006, 63(11):1209-1216.
14. Thorpe L, Groulx B: Depressive syndromes in dementia.  The
Canadian journal of neurological sciences 2001, 28 Suppl 1:S83-95.
15. Nishimura AL, Guindalini C, Oliveira JR, Nitrini R, Bahia VS, de Brito-
Marques PR, Otto PA, Zatz M: Monoamine oxidase a polymor-
phism in Brazilian patients: risk factor for late-onset Alzhe-
imer's disease?  J Mol Neurosci 2005, 27(2):213-217.
16. Wu CK, Mesulam MM, Geula C: Age-related loss of calbindin
from human basal forebrain cholinergic neurons.  Neuroreport
1997, 8(9-10):2209-2213.
17. Emilsson L, Saetre P, Balciuniene J, Castensson A, Cairns N, Jazin EE:
Increased monoamine oxidase messenger RNA expression
levels in frontal cortex of Alzheimer's disease patients.  Neu-
roscience letters 2002, 326(1):56-60.
18. Takehashi M, Tanaka S, Masliah E, Ueda K: Association of
monoamine oxidase A gene polymorphism with Alzheimer's
disease and Lewy body variant.  Neuroscience letters 2002,
327(2):79-82.
19. Amrein R, Martin JR, Cameron AM: Moclobemide in patients
with dementia and depression.  Advances in neurology 1999,
80:509-519.
20. Gareri P, Falconi U, De Fazio P, De Sarro G: Conventional and
new antidepressant drugs in the elderly.  Progress in neurobiology
2000, 61(4):353-396.
21. Rosenzweig P, Patat A, Zieleniuk I, Cimarosti I, Allain H, Gandon JM:
Cognitive performance in elderly subjects after a single dose
of befloxatone, a new reversible selective monoamine oxi-BMC Neuroscience 2007, 8:73 http://www.biomedcentral.com/1471-2202/8/73
Page 9 of 10
(page number not for citation purposes)
dase A inhibitor.  Clinical pharmacology and therapeutics 1998,
64(2):211-222.
22. Malorni W, Giammarioli AM, Matarrese P, Pietrangeli P, Agostinelli E,
Ciaccio A, Grassilli E, Mondovi B: Protection against apoptosis by
monoamine oxidase A inhibitors.  FEBS letters 1998,
426(1):155-159.
23. Maher P, Davis JB: The role of monoamine metabolism in oxi-
dative glutamate toxicity.  J Neurosci 1996, 16(20):6394-6401.
24. Maragos WF, Young KL, Altman CS, Pocernich CB, Drake J, Butter-
field DA, Seif I, Holschneider DP, Chen K, Shih JC: Striatal damage
and oxidative stress induced by the mitochondrial toxin
malonate are reduced in clorgyline-treated rats and MAO-A
deficient mice.  Neurochemical research 2004, 29(4):741-746.
25. Ou XM, Chen K, Shih JC: Monoamine oxidase A and repressor
R1 are involved in apoptotic signaling pathway.  Proceedings of
the National Academy of Sciences of the United States of America 2006,
103(29):10923-10928.
26. Ward MW, Kushnareva Y, Greenwood S, Connolly CN: Cellular
and subcellular calcium accumulation during glutamate-
induced injury in cerebellar granule neurons.  Journal of neuro-
chemistry 2005, 92(5):1081-1090.
27. Rao VL: Nitric oxide in hepatic encephalopathy and hyperam-
monemia.  Neurochemistry international 2002, 41(2-3):161-170.
28. Mousseau DD, Baker GB, Butterworth RF: Increased density of
catalytic sites and expression of brain monoamine oxidase A
in humans with hepatic encephalopathy.  Journal of neurochemis-
try 1997, 68(3):1200-1208.
29. Egashira T, Sakai K, Sakurai M, Takayama F: Calcium disodium ede-
tate enhances type A monoamine oxidase activity in monkey
brain.  Biological trace element research 2003, 94(3):203-211.
30. Samantaray S, Chandra G, Mohanakumar KP: Calcium channel
agonist, (+/-)-Bay K8644, causes a transient increase in stri-
atal monoamine oxidase activity in Balb/c mice.  Neuroscience
letters 2003, 342(1-2):73-76.
31. Kosenko EA, Venediktova NI, Kaminskii Iu G: [Calcium and
ammonia stimulate monoamine oxidase A activity in brain
mitochondria].  Izvestiia Akademii nauk 2003:542-546.
32. Kabuto H, Yokoi I, Mori A, Murakami M, Sawada S: Neurochemical
changes related to ageing in the senescence-accelerated
mouse brain and the effect of chronic administration of
nimodipine.  Mechanisms of ageing and development 1995, 80(1):1-9.
33. Zatta P, Nicosia V, Zambenedetti P: Evaluation of MAO activities
on murine neuroblastoma cells upon acute or chronic treat-
ment with aluminium (III) or tacrine.  Neurochemistry interna-
tional 1998, 32(3):273-279.
34. Bu J, Sathyendra V, Nagykery N, Geula C: Age-related changes in
calbindin-D28k, calretinin, and parvalbumin-immunoreac-
tive neurons in the human cerebral cortex.  Experimental neu-
rology 2003, 182(1):220-231.
35. Geula C, Nagykery N, Wu CK, Bu J: Loss of calbindin-D28K from
aging human cholinergic basal forebrain: relation to plaques
and tangles.  Journal of neuropathology and experimental neurology
2003, 62(6):605-616.
36. Kirischuk S, Pronchuk N, Verkhratsky A: Measurements of intra-
cellular calcium in sensory neurons of adult and old rats.  Neu-
roscience 1992, 50(4):947-951.
37. Holt A, Baker GB: Inhibition of rat brain monoamine oxidase
enzymes by fluoxetine and norfluoxetine.  Naunyn-Schmiede-
berg's archives of pharmacology 1996, 354(1):17-24.
38. Shih JC: Molecular basis of human MAO A and B.  Neuropsychop-
harmacology 1991, 4(1):1-7.
39. Jenner P, Olanow CW: Oxidative stress and the pathogenesis of
Parkinson's disease.  Neurology 1996, 47(6 Suppl 3):S161-70.
40. Kennedy BP, Ziegler MG, Alford M, Hansen LA, Thal LJ, Masliah E:
Early and persistent alterations in prefrontal cortex MAO A
and B in Alzheimer's disease.  J Neural Transm 2003,
110(7):789-801.
41. Sherif F, Gottfries CG, Alafuzoff I, Oreland L: Brain gamma-ami-
nobutyrate aminotransferase (GABA-T) and monoamine
oxidase (MAO) in patients with Alzheimer's disease.  Journal
of neural transmission 1992, 4(3):227-240.
42. Altura BM: Calcium antagonist properties of magnesium:
implications for antimigraine actions.  Magnesium 1985,
4(4):169-175.
43. Montero M, Alonso MT, Carnicero E, Cuchillo-Ibanez I, Albillos A,
Garcia AG, Garcia-Sancho J, Alvarez J: Chromaffin-cell stimula-
tion triggers fast millimolar mitochondrial Ca2+ transients
that modulate secretion.  Nature cell biology 2000, 2(2):57-61.
44. Rizzuto R, Pozzan T: Microdomains of intracellular Ca2+:
molecular determinants and functional consequences.  Physi-
ological reviews 2006, 86(1):369-408.
45. Robb-Gaspers LD, Burnett P, Rutter GA, Denton RM, Rizzuto R,
Thomas AP: Integrating cytosolic calcium signals into mito-
chondrial metabolic responses.  The EMBO journal 1998,
17(17):4987-5000.
46. White RJ, Reynolds IJ: Mitochondria accumulate Ca2+ following
intense glutamate stimulation of cultured rat forebrain neu-
rones.  The Journal of physiology 1997, 498 ( Pt 1):31-47.
47. Herrington J, Park YB, Babcock DF, Hille B: Dominant role of
mitochondria in clearance of large Ca2+ loads from rat adre-
nal chromaffin cells.  Neuron 1996, 16(1):219-228.
48. Xu T, Naraghi M, Kang H, Neher E: Kinetic studies of Ca2+ bind-
ing and Ca2+ clearance in the cytosol of adrenal chromaffin
cells.  Biophysical journal 1997, 73(1):532-545.
49. Duchen MR: Contributions of mitochondria to animal physiol-
ogy: from homeostatic sensor to calcium signalling and cell
death.  The Journal of physiology 1999, 516 ( Pt 1):1-17.
50. Baimbridge KG, Celio MR, Rogers JH: Calcium-binding proteins
in the nervous system.  Trends in neurosciences 1992,
15(8):303-308.
51. Wu CK, Nagykery N, Hersh LB, Scinto LF, Geula C: Selective age-
related loss of calbindin-D28k from basal forebrain choliner-
gic neurons in the common marmoset (Callithrix jacchus).
Neuroscience 2003, 120(1):249-259.
52. Palop JJ, Jones B, Kekonius L, Chin J, Yu GQ, Raber J, Masliah E, Mucke
L: Neuronal depletion of calcium-dependent proteins in the
dentate gyrus is tightly linked to Alzheimer's disease-related
cognitive deficits.  Proceedings of the National Academy of Sciences of
the United States of America 2003, 100(16):9572-9577.
53. Thibault O, Porter NM, Chen KC, Blalock EM, Kaminker PG, Clod-
felter GV, Brewer LD, Landfield PW: Calcium dysregulation in
neuronal aging and Alzheimer's disease: history and new
directions.  Cell calcium 1998, 24(5-6):417-433.
54. Chan-Palay V, Hochli M, Savaskan E, Hungerecker G: Calbindin D-
28k and monoamine oxidase A immunoreactive neurons in
the nucleus basalis of Meynert in senile dementia of the
Alzheimer type and Parkinson's disease.  Dementia (Basel, Swit-
zerland) 1993, 4(1):1-15.
55. Yenari MA, Minami M, Sun GH, Meier TJ, Kunis DM, McLaughlin JR,
Ho DY, Sapolsky RM, Steinberg GK: Calbindin d28k overexpres-
sion protects striatal neurons from transient focal cerebral
ischemia.  Stroke; a journal of cerebral circulation 2001,
32(4):1028-1035.
56. Phillips RG, Meier TJ, Giuli LC, McLaughlin JR, Ho DY, Sapolsky RM:
Calbindin D28K gene transfer via herpes simplex virus
amplicon vector decreases hippocampal damage in vivo fol-
lowing neurotoxic insults.  Journal of neurochemistry 1999,
73(3):1200-1205.
57. Wernyj RP, Mattson MP, Christakos S: Expression of calbindin-
D28k in C6 glial cells stabilizes intracellular calcium levels
and protects against apoptosis induced by calcium iono-
phore and amyloid beta-peptide.  Brain research 1999,
64(1):69-79.
58. Mattson MP, Rychlik B, Chu C, Christakos S: Evidence for calcium-
reducing and excito-protective roles for the calcium-binding
protein calbindin-D28k in cultured hippocampal neurons.
Neuron 1991, 6(1):41-51.
59. Brorson JR, Bindokas VP, Iwama T, Marcuccilli CJ, Chisholm JC, Miller
RJ: The Ca2+ influx induced by beta-amyloid peptide 25-35 in
cultured hippocampal neurons results from network excita-
tion.  Journal of neurobiology 1995, 26(3):325-338.
60. Quevedo J, Vianna M, Daroit D, Born AG, Kuyven CR, Roesler R,
Quillfeldt JA: L-type voltage-dependent calcium channel
blocker nifedipine enhances memory retention when infused
into the hippocampus.  Neurobiology of learning and memory 1998,
69(3):320-325.
61. Heidrich A, Rosler M, Riederer P: [Pharmacotherapy of Alzhe-
imer dementia: therapy of cognitive symptoms--new results
of clinical studies].  Fortschritte der Neurologie-Psychiatrie 1997,
65(3):108-121.
62. Yamada M, Itoh Y, Suematsu N, Otomo E, Matsushita M: Apolipo-
protein E genotype in elderly nondemented subjects withoutPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Neuroscience 2007, 8:73 http://www.biomedcentral.com/1471-2202/8/73
Page 10 of 10
(page number not for citation purposes)
senile changes in the brain.  Annals of neurology 1996,
40(2):243-245.
63. Yew DT, Chan WY: Early appearance of acetylcholinergic,
serotoninergic, and peptidergic neurons and fibers in the
developing human central nervous system.  Microscopy research
and technique 1999, 45(6):389-400.
64. Smith IF, Green KN, LaFerla FM: Calcium dysregulation in Alzhe-
imer's disease: recent advances gained from genetically
modified animals.  Cell calcium 2005, 38(3-4):427-437.
65. Supnet C, Grant J, Kong H, Westaway D, Mayne M: Amyloid-beta-
(1-42) increases ryanodine receptor-3 expression and func-
tion in neurons of TgCRND8 mice.  The Journal of biological chem-
istry 2006, 281(50):38440-38447.
66. Burke WJ, Li SW, Chung HD, Ruggiero DA, Kristal BS, Johnson EM,
Lampe P, Kumar VB, Franko M, Williams EA, Zahm DS: Neurotox-
icity of MAO metabolites of catecholamine neurotransmit-
ters: role in neurodegenerative diseases.  Neurotoxicology 2004,
25(1-2):101-115.
67. Liu Y, Piasecki D: A cell-based method for the detection of
nanomolar concentrations of bioactive amyloid.  Analytical bio-
chemistry 2001, 289(2):130-136.